Alzheimer's Disease — Animal Models & Behavioral Testing

There is no single best model — it depends on your research question. 5xFAD is ideal for rapid drug screening due to aggressive amyloid onset by 2 months. APP/PS1 suits longitudinal studies with its slower progression. 3xTg-AD is the only widely used model with both plaques and tangles. Scopolamine provides a fast, reversible cholinergic deficit model that requires no transgenic colony.

5xFAD carries five familial AD mutations and develops plaques by 2 months with cognitive deficits by 4–5 months — it is an aggressive, fast-onset model. APP/PS1 has two mutations with plaque onset around 6 months and cognitive impairment at 6–8 months, making it better for longitudinal intervention studies where a wider therapeutic window is needed.

The core battery includes the Morris Water Maze (spatial learning and memory), Y-Maze spontaneous alternation (working memory), Barnes Maze (dry-land spatial learning), fear conditioning (associative memory), and novel object recognition (recognition memory). The specific battery depends on the model: transgenic models typically use MWM and fear conditioning, while pharmacological models like scopolamine pair well with Y-Maze and passive avoidance for rapid screening.

Scopolamine is a muscarinic acetylcholine receptor antagonist that produces acute, reversible cognitive impairment when injected intraperitoneally (typically 1–3 mg/kg). It mimics the cholinergic deficit seen in AD but does not produce amyloid plaques or tau tangles. It is widely used for rapid screening of pro-cognitive compounds because deficits appear within 30 minutes and resolve within hours.

5xFAD mice develop intraneuronal amyloid-beta accumulation as early as 1.5 months, with extracellular amyloid plaques visible by 2 months of age. Plaque burden increases progressively, and significant neuronal loss occurs in cortical layer 5 and the subiculum by 9 months. Cognitive deficits on behavioral tasks like the Morris Water Maze are typically detectable from 4–5 months.

The 3xTg-AD model is the only widely used transgenic model that develops both amyloid-beta plaques (from ~6 months) and tau-based neurofibrillary tangles (from ~12 months). It carries three mutations: APP Swedish, PSEN1 M146V, and Tau P301L. This dual pathology makes it uniquely valuable for studying the interaction between amyloid and tau cascades.

Both test hippocampal-dependent spatial learning, but they differ in stress profile and practicality. The Morris Water Maze uses swimming as motivation and is the most widely published spatial memory assay — reviewers expect it. The Barnes Maze uses bright light and noise aversion on a dry platform, producing less swim-stress and less hypothermia risk in aged mice. Barnes Maze also allows repeated testing more easily. Choose MWM for maximum comparability with published data; choose Barnes for reduced stress or when testing aged or frail animals.

Yes. Scopolamine produces cholinergic deficits across strains, though response magnitude varies. ICR/CD-1 and C57BL/6J are the most commonly used and best characterized. Outbred strains (CD-1) offer lower cost and genetic diversity; inbred C57BL/6J provides tighter data with smaller group sizes. Always run a pilot dose–response study when using scopolamine with a new strain.